EMA Accepts Teva's Application for Long-Acting Schizophrenia Treatment

The European Medicines Agency (EMA) has accepted Teva Pharmaceuticals' Marketing Authorization Application for a long-acting injectable version of Olanzapine (TEV-‘749). This formulation targets adults with schizophrenia and is developed in collaboration with Medincell. Designed for administration every four weeks, the treatment seeks to improve adherence and long-term management of the disorder.

TEV-‘749 could address a significant gap in current schizophrenia therapies by offering a viable long-acting option. It uses Medincell's proprietary SteadyTeq™ technology for controlled release. The application is supported by extensive clinical trials, including the Phase 3 SOLARIS study. The treatment aims to stabilize patient outcomes by offering proven efficacy in a manageable format.

Schizophrenia affects between 0.3% and 1.5% of the European population, posing challenges like social isolation and reduced life expectancy. Currently, daily oral Olanzapine is typical, but adherence remains challenging. This development could provide new avenues for managing the disorder.